Eli Lilly and top Alzheimer’s disease experts are asking for more investment in tools and resources to diagnose Alzheimer’s across Europe. This comes after new information was shared at a conference in Belgium. The data shows that many people with Alzheimer’s disease (AD) are not being properly diagnosed. In fact, fewer than one in five patients get the necessary tests to confirm they have the disease. Even though over 70% of doctors think these tests are important, they are not being used enough. Professor Lutz Frölich, a leading expert in this field, said, ‘We are at a crucial point. The choices we make now will affect how Alzheimer’s is treated in Europe in the future. We have the tools to manage Alzheimer’s better in its early stages, which could lessen the impact of the disease. But this can only happen if we can diagnose it quickly and fairly for everyone.’ The survey also found that there are long waits to see specialists. For example, in Spain and France, patients sometimes wait up to seven months. Stigma and lack of awareness are also big reasons why people don’t seek help early. Jean Georges, from Alzheimer Europe, said, ‘These findings show a worrying picture of Alzheimer’s diagnosis in Europe. Many patients and families we support are often left waiting too long for answers.’ Dr Stéphane Epelbaum, from Eli Lilly, added, ‘It’s important to diagnose Alzheimer’s quickly and accurately so patients can get the best care possible.’